Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 The Female ... host an investor conference call to discuss its operating ... September 30, 2014 on Tuesday, December 2, 2014 at ... to report its operating results earlier the same day. ... in the conference call by dialing 1-877-374-8416 (international participants ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
(Date:11/24/2014)... , Nov. 24, 2014  Rigel Pharmaceuticals, Inc. (Nasdaq: ... is retiring from the board of directors and from ... Raul Rodriguez , most recently serving as the company,s president ... executive officer and join the board of directors.  Gary ... 2005, will become chairman. Mr. Gower is expected to remain ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3
... Ala., Nov. 19 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ... 5,000,000 shares of its common stock at $9.75 per share, ... the shares are being offered by BioCryst pursuant to an ... Exchange Commission. BioCryst has also granted the underwriters a ...
... , TAINAN, ... global,supplier of active pharmaceutical ingredients (APIs), announced that ... Certification from,SafeBridge(R) Consultants, Inc. The Certification confirms ScinoPharm,s,competency ... active,pharmaceutical ingredients (APIs), and applies to specific laboratories ...
Cached Medicine Technology:BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2
(Date:11/26/2014)... Washington, DC (PRWEB) November 26, 2014 ... Inc.’s (AIS) independently published The AIS Report on Blue ... Inc. and WellPoint, Inc. on the varied strategies the ... costs and improve compliance with treatments for sleep apnea, ... The sleep disorder, because it’s linked to increased rates ...
(Date:11/26/2014)... Los Angeles, CA (PRWEB) November 26, 2014 ... Los Angeles orthopedic surgeon Dr. Steven Meier has ... site to offer current and prospective patients an online ... , “We’re really excited to present the new and ... and added features make it easier than ever for ...
(Date:11/26/2014)... GI for Life announced today, that they ... of their popular nutritional supplements: ColoVite Colon Health ... Discounts of 40% will be offered for a limited ... ColoVite supplement is a scientifically formulated vitamin supplement developed ... easy-to-take colon vitamin with ALL the nutrients associated with ...
(Date:11/26/2014)... Sonru, the video interviewing specialist, has today ... and Chief Marketing Officer, in addition to the formal ... Jones has been appointed as Chief Operating Officer. He ... of Chief Marketing Officer. , Mr Jones is a ... includes senior roles with The Walt Disney Company and ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... generate far more than those who do moderate exercise, study ... new study provides tantalizing clues about how exercise helps ward ... fat-burning molecules in their blood than less fit people after ... on a biochemical level, at generating fat-burning molecules that break ...
... ... Mondadori this ,practical guide teaches Latina women how to project their best image, ... New York, NY ... Your Style: Your Guide to Dressing Better) written by Martín Llorens, renowned fashion ...
... (May 27, 2010) New research from the University of Minnesota,s ... use of indoor tanning devices to increased risk of melanoma, the ... 2,268 Minnesotans is the largest of its kind. It found: ... any amount of time are 74 percent more likely to develop ...
... Approximately 49 million people, including 17 million children, experience ... to sustain the nutritional needs of family members ... number may be even higher when examining the specific ... Missouri study, researchers found that food insecurity and hunger ...
... ... Aging today introduced “Beautiful Minds: Finding Your Lifelong Potential,” an educational campaign designed to ... ... Martek Biosciences (NASDAQ: MATK), in partnership with the National Center for ...
... Study found number treated within two weeks of diagnosis ... -- Switching to electronic medical records can significantly boost ... are treated, a new study shows. , Researchers found ... the percentage of patients treated within two weeks of ...
Cached Medicine News:Health News:Fit People Release More Fat-Burning Molecules During Exercise 2Health News:Fit People Release More Fat-Burning Molecules During Exercise 3Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:U of M study definitively links indoor tanning to melanoma 2Health News:Despite food-assistance programs, many children experience food insecurity, hunger 2Health News:Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential" 2Health News:Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential" 3Health News:Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential" 4Health News:Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential" 5
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: